Maine Medical Center
- Type
- Teaching hospital
- Where
- PORTLAND, ME
- Medicare CCN
- 200009
- Received
- $1,247,363 in 217 records, 2021 ($47,792 general, $1,199,571 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Maine Medical Center Fuzzy (name and state)
- Lobbying client: MAINE MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: Maine Medical Center Fuzzy (name and state)
- Trademark owner: Maine Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 47 | $47,792 |
| 2021 | Research payment | 170 | $1,199,571 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 170 | $1,199,571 |
| Long term medical supply or device loan | 13 | $10,427 |
| Royalty or License | 2 | $9,708 |
| Space rental or facility fees (teaching hospital only) | 2 | $9,435 |
| Debt forgiveness | 17 | $6,152 |
| Education | 8 | $5,937 |
| Gift | 1 | $2,994 |
| Charitable Contribution | 1 | $2,500 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $400 |
| Food and Beverage | 2 | $238 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | SERVIER PHARMACEUTICALS LLC | $5,314 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | GlaxoSmithKline, LLC. | $4,424 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2021 | |
| 2021-12-31 | Medical Device Business Services, Inc. | $431 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-12-31 | Medline Industries LP | $375 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $125 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $118 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $38 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Stryker Corporation | $27 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-23 | SERVIER PHARMACEUTICALS LLC | $1,108 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-23 | Kowa Research Institute, Inc. | $1,053 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $1,414 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $723 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $715 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $652 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Stryker Corporation | $280 | Research payment | Cash or cash equivalent | SURPASS EVOLVE Device, FLOW DIVERTER | EVOLVE | 2021 |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $226 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-20 | Genentech, Inc. | $2,836 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB RMS HIGH DOSE STUDY | 2021 |
| 2021-12-15 | Kowa Research Institute, Inc. | $468 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-12-13 | Medical Device Business Services, Inc. | $2,928 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-12-10 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-12-01 | Kowa Research Institute, Inc. | $2,106 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-12-01 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-11-29 | Medical Device Business Services, Inc. | $4,803 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-11-23 | GlaxoSmithKline, LLC. | $3,236 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $225 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $25 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-11-18 | Janssen Research & Development, LLC | $6,471 | Research payment | Cash or cash equivalent | A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease | 2021 | |
| 2021-11-18 | Janssen Research & Development, LLC | $2,215 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2021 | |
| 2021-11-15 | FUJIFILM SonoSite, Inc. | $777 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-11-11 | FUJIFILM SonoSite, Inc. | $393 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-11-10 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-11-10 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-10 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-11-09 | FUJIFILM SonoSite, Inc. | $162 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-11-01 | Genentech, Inc. | $4,147 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2021 |
| 2021-10-27 | Vero Biotech Inc. | $177 | Food and Beverage | Cash or cash equivalent | Genosyl Drug, Respiratory Therapy | 2021 | |
| 2021-10-26 | GlaxoSmithKline, LLC. | $6,749 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-10-26 | Clovis Oncology, Inc. | $1,282 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2021 |
| 2021-10-25 | Kowa Research Institute, Inc. | $1,638 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-10-22 | Genentech, Inc. | $7,900 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB PPMS HIGH DOSE STUDY | 2021 |
| 2021-10-22 | Genentech, Inc. | $7,900 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB RMS HIGH DOSE STUDY | 2021 |
| 2021-10-19 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-10-18 | FUJIFILM SonoSite, Inc. | $325 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-10-14 | Genentech, Inc. | $111,861 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-10-14 | Genentech, Inc. | $1,682 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-10-14 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $150 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-14 | Penumbra, Inc. | $150 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-10-11 | Medical Device Business Services, Inc. | $1,550 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-10-06 | SANOFI PASTEUR INC. | $8,395 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2021 | |
| 2021-10-04 | Boston Scientific Corporation | $320 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASAP TOO | 2021 |
| 2021-10-01 | ABBVIE INC. | $1,836 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira (Adalimumab) in Pediatri | 2021 |
| 2021-09-30 | GlaxoSmithKline, LLC. | $4,782 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2021 | |
| 2021-09-30 | FUJIFILM SonoSite, Inc. | $777 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-09-24 | Kowa Research Institute, Inc. | $1,521 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-09-23 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-23 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-09-22 | Endologix LLC | $61,024 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2021 | |
| 2021-09-20 | SERVIER PHARMACEUTICALS LLC | $5,314 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-09-20 | Bayer Healthcare Pharmaceuticals Inc. | $3,347 | Research payment | Cash or cash equivalent | Vitrakvi Drug, Oncology | Observational Study Agreement - Bayer is conducting a prospective non-interventional (observational) study entitled ON-T | 2021 |
| 2021-09-20 | Johnson & Johnson Health Care Systems Inc. | $336 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-17 | Genentech, Inc. | $27,368 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB RMS HIGH DOSE STUDY | 2021 |
| 2021-09-15 | Novocure GmbH | $2,133 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-09-14 | GlaxoSmithKline, LLC. | $6,123 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-09-13 | Genentech, Inc. | $9,251 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-09-10 | Medical Device Business Services, Inc. | $1,464 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-09-06 | Novocure GmbH | $16,328 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-09-01 | Genentech, Inc. | $8,000 | Royalty or License | Cash or cash equivalent | Drug | 2021 | |
| 2021-08-27 | Smith+Nephew, Inc. | $34,000 | Research payment | Cash or cash equivalent | ANTHOLOGY Device, Recon Hips | Data Capture relating to the ABLE approach for hip replacement | 2021 |
| 2021-08-26 | Penumbra, Inc. | $3,500 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-08-25 | Janssen Research & Development, LLC | $22,440 | Research payment | Cash or cash equivalent | A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease | 2021 | |
| 2021-08-24 | Kowa Research Institute, Inc. | $1,638 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-08-24 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-08-23 | GENZYME CORPORATION | $600 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-08-19 | Penumbra, Inc. | $800 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-08-11 | Genentech, Inc. | $18,828 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2021 |
| 2021-08-10 | Clovis Oncology, Inc. | $4,637 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2021 |
| 2021-08-03 | Clovis Oncology, Inc. | $3,750 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2021 |
| 2021-08-03 | Ipsen Bioscience Inc. | $1,432 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-08-02 | Medical Device Business Services, Inc. | $1,464 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-08-01 | Vero Biotech Inc. | $60 | Food and Beverage | Cash or cash equivalent | Genosyl Drug, Respiratory Therapy | 2021 | |
| 2021-07-28 | CSL Behring | $1,200 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-07-28 | CSL Behring | $550 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-07-27 | FUJIFILM SonoSite, Inc. | $935 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-07-23 | Kowa Research Institute, Inc. | $2,691 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-07-15 | ABBVIE INC. | $2,465 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira (Adalimumab) in Pediatri | 2021 |
| 2021-07-15 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-15 | Penumbra, Inc. | $700 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-15 | Penumbra, Inc. | $550 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-15 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-15 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-15 | Penumbra, Inc. | $175 | Research payment | Cash or cash equivalent | Penumbra System Device, Neurointervention | INSIGHT | 2021 |
| 2021-07-14 | GlaxoSmithKline, LLC. | $39,321 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2021 | |
| 2021-07-14 | Medtronic, Inc. | $2,364 | Research payment | Cash or cash equivalent | Endurant EVO US | 2021 | |
| 2021-07-13 | Zimmer Biomet Holdings, Inc. | $2,994 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2021 | |
| 2021-07-13 | GlaxoSmithKline, LLC. | $2,705 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-07-01 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-06-30 | GlaxoSmithKline, LLC. | $6,161 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2021 | |
| 2021-06-25 | EMD Serono, Inc. | $880 | Research payment | Cash or cash equivalent | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 | |
| 2021-06-23 | Kowa Research Institute, Inc. | $1,638 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-06-22 | GlaxoSmithKline, LLC. | $9,745 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-06-18 | FUJIFILM SonoSite, Inc. | $719 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-06-13 | Amgen Inc. | $1,325 | Research payment | In-kind items and services | LUMAKRAS Drug, Oncology | AMG 510 Expanded access ex EU (w/LTFU) | 2021 |
| 2021-06-03 | Janssen Research & Development, LLC | $10,908 | Research payment | Cash or cash equivalent | A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease | 2021 | |
| 2021-05-28 | Medical Device Business Services, Inc. | $324 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2021 |
| 2021-05-25 | Kowa Research Institute, Inc. | $1,872 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-05-24 | SK Life Science, Inc. | $3,410 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | YKP3089C033 | 2021 |
| 2021-05-24 | Janssen Research & Development, LLC | $2,002 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2021 | |
| 2021-05-24 | SK Life Science, Inc. | $1,965 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | YKP3089C025 | 2021 |
| 2021-05-24 | Johnson & Johnson Health Care Systems Inc. | $101 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-21 | VERTEX PHARMACEUTICALS INCORPORATED | $25,000 | Research payment | Cash or cash equivalent | An Observational Study to Evaluate the Real-world Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Ill | 2021 | |
| 2021-05-12 | Johnson & Johnson Health Care Systems Inc. | $10 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-09 | Smith+Nephew, Inc. | $1,069 | Debt forgiveness | Cash or cash equivalent | Softsilk Device, Sports Med Knee | 2021 | |
| 2021-05-05 | SERVIER PHARMACEUTICALS LLC | $1,108 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-05-04 | GlaxoSmithKline, LLC. | $6,566 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-05-03 | Genentech, Inc. | $8,487 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2021 |
| 2021-05-03 | Abbott Laboratories | $2,500 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-05-03 | Ipsen Bioscience Inc. | $2,149 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-04-26 | FUJIFILM SonoSite, Inc. | $1,845 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-04-26 | Kowa Research Institute, Inc. | $1,170 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-04-20 | GlaxoSmithKline, LLC. | $11,561 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-04-19 | ACADIA Pharmaceuticals Inc | $7,500 | Research payment | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | ACP-103-063 | 2021 |
| 2021-04-19 | Cochlear Americas | $27 | Debt forgiveness | Cash or cash equivalent | Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode Device, Implantable hearing solution | 2021 | |
| 2021-04-15 | JAZZ PHARMACEUTICALS INC. | $71,136 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2021 |
| 2021-04-15 | Smith+Nephew, Inc. | $26,000 | Research payment | Cash or cash equivalent | ANTHOLOGY Device, Recon Hips | Data Capture relating to the ABLE approach for hip replacement | 2021 |
| 2021-04-15 | Smith+Nephew, Inc. | $19,500 | Research payment | Cash or cash equivalent | ANTHOLOGY Device, Recon Hips | Data Capture relating to the ABLE approach for hip replacement | 2021 |
| 2021-04-15 | Smith+Nephew, Inc. | $6,500 | Research payment | Cash or cash equivalent | ANTHOLOGY Device, Recon Hips | Data Capture relating to the ABLE approach for hip replacement | 2021 |
| 2021-04-14 | EMD Serono, Inc. | $15,000 | Research payment | Cash or cash equivalent | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 | |
| 2021-04-14 | EMD Serono, Inc. | $1,500 | Research payment | Cash or cash equivalent | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 | |
| 2021-04-12 | SERVIER PHARMACEUTICALS LLC | $13,619 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-04-12 | SERVIER PHARMACEUTICALS LLC | $1,108 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-04-08 | Edwards Lifesciences Corporation | $3,935 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-04-06 | AKEBIA THERAPEUTICS INC | $3,909 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-04-05 | PFIZER INC. | $2,150 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2021 |
| 2021-03-30 | Genentech, Inc. | $841 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-03-29 | Medical Device Business Services, Inc. | $4,632 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-03-26 | Janssen Research & Development, LLC | $957 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2021 | |
| 2021-03-25 | Biogen, Inc. | $24,854 | Research payment | Cash or cash equivalent | Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Follo | 2021 | |
| 2021-03-25 | Clovis Oncology, Inc. | $4,736 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2021 |
| 2021-03-25 | Eli Lilly and Company | $3,791 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-03-22 | Eli Lilly and Company | $76,930 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-03-22 | Kowa Research Institute, Inc. | $2,691 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-03-15 | Genentech, Inc. | $10,981 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2021 |
| 2021-03-12 | Ipsen Bioscience Inc. | $35,775 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-03-10 | CSL Behring | $1 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-03-03 | Genentech, Inc. | $5,046 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-03-02 | Ipsen Bioscience Inc. | $716 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patient | 2021 |
| 2021-03-01 | Kowa Research Institute, Inc. | $1,170 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2021 |
| 2021-02-26 | Janssen Research & Development, LLC | $2,407 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2021 | |
| 2021-02-24 | EMD Millipore Corporation | $1,708 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2021 | |
| 2021-02-23 | Abbott Laboratories | $4,620 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-02-23 | GENZYME CORPORATION | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | THYMOGLOBULIN Biological, Oncology | 2021 | |
| 2021-02-22 | GENZYME CORPORATION | $350 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-02-19 | Biogen, Inc. | $2,089 | Research payment | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | Plegridy Observational Program | 2021 |
| 2021-02-18 | LivaNova USA, Inc. | $4,746 | Research payment | Cash or cash equivalent | Perceval Device, Cardiology/Vascular Diseases | Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant (Believe) | 2021 |
| 2021-02-17 | GlaxoSmithKline, LLC. | $22,847 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-02-15 | Boston Scientific Corporation | $320 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASAP TOO | 2021 |
| 2021-02-11 | ABBVIE INC. | $3,500 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira (Adalimumab) in Pediatri | 2021 |
| 2021-02-11 | Janssen Research & Development, LLC | $2,225 | Research payment | Cash or cash equivalent | A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease | 2021 | |
| 2021-02-05 | ACADIA Pharmaceuticals Inc | $14,000 | Research payment | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | ACA 16-cAC-0001 | 2021 |
| 2021-02-05 | ACADIA Pharmaceuticals Inc | $14,000 | Research payment | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | ACA 16-cAC-0001 | 2021 |
| 2021-02-05 | CSL Behring | $5,700 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-02-05 | CSL Behring | $2,800 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-02-05 | CSL Behring | $1,200 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2021 | |
| 2021-02-02 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-29 | Welch Allyn | $113 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-01-28 | Amgen Inc. | $101,781 | Research payment | In-kind items and services | Repatha Biological, Cardiology | A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG) | 2021 |
| 2021-01-28 | LivaNova USA, Inc. | $3,008 | Research payment | Cash or cash equivalent | Perceval Device, Cardiology/Vascular Diseases | Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant (Believe) | 2021 |
| 2021-01-27 | Johnson & Johnson Health Care Systems Inc. | $115 | Debt forgiveness | In-kind items and services | 2021 |
The latest 200 records of 217.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Portland, ME, county Cumberland County, ME, state Maine; placed by its city name.
| Measure | Place (city or town) Portland, ME | County Cumberland County, ME | State Maine |
|---|---|---|---|
| Population B01003 | 68,854 | 308,827 | 1,387,817 |
| Population, 2020 census P1 | 68,408 | 303,069 | 1,362,359 |
| Median age B01002 | 37.8 | 42.2 | 44.8 |
| Under 18 B01001 | 15.4% | 18.0% | 18.1% |
| 65 and over B01001 | 16.9% | 20.4% | 22.4% |
| Households B11001 | 32,965 | 132,168 | 597,159 |
| Foreign born B05002 | 11.8% | 6.7% | 4.1% |
| Median household income B19013 | $79,540 | $95,677 | $74,733 |
| Median family income B19113 | $118,777 | $124,273 | $96,912 |
| Per capita income B19301 | $52,781 | $55,739 | $43,742 |
| Poverty rate B17001 | 11.2% | 7.3% | 10.7% |
| Unemployment rate B23025 | 4.2% | 3.1% | 3.8% |
| Civilian labor force B23025 | 42,094 | 175,357 | 719,683 |
| Mean commute (minutes) B08013 | 19.4 | 23.2 | 24.6 |
| Bachelor's degree or higher B15003 | 59.7% | 53.0% | 36.2% |
| Housing units B25001 | 36,559 | 153,286 | 751,876 |
| Owner-occupied B25003 | 46.9% | 69.8% | 74.3% |
| Renters B25003 | 53.1% | 30.2% | 25.7% |
| Median home value B25077 | $489,600 | $451,200 | $296,600 |
| Median gross rent B25064 | $1,577 | $1,589 | $1,139 |
| White, not Hispanic B03002 | 77.5% | 85.6% | 89.9% |
| Black B03002 | 9.1% | 3.4% | 1.8% |
| Hispanic or Latino B03002 | 3.1% | 2.8% | 2.2% |
| Asian B03002 | 3.9% | 2.2% | 1.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Portland, ME.
Comments